<DOC>
	<DOCNO>NCT00913367</DOCNO>
	<brief_summary>The purpose study compare efficacy Amaryl®M 1/500 mg twice daily versus Amaryl® 4 mg combination Lantus® once-daily regimen type 2 Diabetes Mellitus patient inadequate glycemic control .</brief_summary>
	<brief_title>Efficacy/Safety Study Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both Combination With Lantus® Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>There several kind oral antidiabetic drug ( OADs ) use treatment patient type 2 DM . Among , sulfonylurea metformin well-established first-line OADs . However , beta cell dysfunction progress time , patient fail achieve good glycemic control OADs alone need treatment intensification , usually involve introduction insulin either alone combination OADs . Now , OAD combine bedtime insulin one recommend treatment option patient type 2 DM OAD failure . But , still remain unclear OADs effective combination insulin treatment type 2 DM . , study able verify OADs effective combination insulin treatment type 2 DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients 20 year old type 2 DM Patients inadequate glycemic control despite continuous use tolerable maximal dose one OADs 3months . 7 % &lt; HbA1c &lt; 11 % screen 21 kg/m2 ≤ BMI ≤ 30 kg/m2 Patents need insulin addon therapy base investigator 's discretion Patients would give informed consent Patients perform SMBG record data patient 's diary History acute metabolic complication diabetic ketoacidosis hyperosmolar nonketotic coma within 3 month screen Pregnant lactate female History drug alcohol abuse Patients know hypersensitivity glimepiride , metformin HCL insulin Nightshift worker Patients insulin therapy screen Treatment investigational product last 3 month screen Clinically significant laboratory abnormality screen labs medical condition would affect completion outcome study base investigator 's decision Patients serum creatinine level &gt; 1.5 mg/dl male &gt; 1.4 mg/dl female Patients ALT AST &gt; 3x ULN</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>